About: Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $14.71 (-4.85%)
ERAS NASDAQ Erasca Inc
Erasca Inc share price
ERAS price activity
Last Price
$14.710
Change (24hr)
-0.75 USD (-4.85%)
Volume
2.38M
Volume (4w avg)
-
Open
$15.25
Day Range
$14.71 - $15.25
Previous Close
$15.46
Last Trade
13 Oct, 6:33 pm GMT+0
Delayed
13 Oct, 6:33 pm GMT+0
ERAS price performance
Delayed
13 Oct, 6:33 pm GMT+0
ERAS Market Signals